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Abstract: Skeletal myopathy encompasses both atrophy and dysfunction and is a prominent event in
cancer and chemotherapy-induced cachexia. Here, we investigate the effects of a chemotherapeutic
agent, 5-fluorouracil (5FU), on skeletal muscle mass and function, and whether small-molecule
therapeutic candidate, BGP-15, could be protective against the chemotoxic challenge exerted by 5FU.
Additionally, we explore the molecular signature of 5FU treatment. Male Balb/c mice received metro-
nomic tri-weekly intraperitoneal delivery of 5FU (23 mg/kg), with and without BGP-15 (15 mg/kg),
6 times in total over a 15 day treatment period. We demonstrated that neither 5FU, nor 5FU combined
with BGP-15, affected body composition indices, skeletal muscle mass or function. Adjuvant BGP-15
treatment did, however, prevent the 5FU-induced phosphorylation of p38 MAPK and p65 NF-κB
subunit, signalling pathways involved in cell stress and inflammatory signalling, respectively. This as
associated with mitoprotection. 5FU reduced the expression of the key cytoskeletal proteins, desmin
and dystrophin, which was not prevented by BGP-15. Combined, these data show that metronomic
delivery of 5FU does not elicit physiological consequences to skeletal muscle mass and function but
is implicit in priming skeletal muscle with a molecular signature for myopathy. BGP-15 has modest
protective efficacy against the molecular changes induced by 5FU.
Keywords: chemotherapy; cachexia; 5-fluorouracil; skeletal muscle; p38; NF-κB; dystrophin; desmin
1. Introduction
Colorectal cancer (CRC) is a significant contributor to worldwide morbidity and mor-
tality, with approximately 1.9 million new CRC cases and 900,000 CRC-related deaths
reported in 2020 (GLOBOCAN 2020) [1]. The underlying causes of CRC progression and
mortality are multi-faceted and still being discovered. A key risk factor that complicates
responsivity to anti-cancer treatment, and, therefore survivability, is the metabolic wasting
syndrome, cachexia, which is prevalent in ~45% of CRC patients [2]. Cachexia is charac-
terised by the ongoing loss of skeletal muscle mass, with or without loss of fat mass, where
patients are non-responsive to nutritional intervention and manifest progressive functional
impairment [3]. Clinically, skeletal muscle atrophy and poor recovery from the loss of
skeletal muscle mass have been established as two prominent prognostic factors of mortal-
ity in cachectic cancer patients [4]. Recently, anti-cancer treatment, i.e., chemotherapy, has
surfaced as a key contributor to the progression of cachexia, with emerging literature sug-
gesting that chemotherapy can induce skeletal muscle mass loss and dysfunction (skeletal
myopathy) [5,6] with lifelong impact [7].
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Chemotherapy is a mainstay of advanced CRC treatment strategies and is used
complementarily to surgical tumour resection or in advanced staging due to metastasis or
resistance to radiotherapy. The anti-metabolite, 5-fluorouracil (5FU), is primarily utilized in
the treatment of advanced CRC as a backbone constituent of multi-agent regimens, such as
FOLFIRI [5FU, leucovorin (LV) and irinotecan (IRI)] and FOLFOX [5FU, LV and oxaliplatin
(OXA)] (for extensive review, see [8]). 5FU administration can elicit significant side-effects
including, but not limited to, cardiotoxicity, gastrointestinal toxicity, neurotoxicity and pan-
cytopenia [9], with lean mass suggested to be an independent determinant of dose-limiting
toxicity from 5FU-based regimens [10]. Barreto et al. have demonstrated that the 5FU-based
FOLFIRI regimen induces a cachectic phenotype in cancer-free mice, underscored by the
loss of body and lean mass, and skeletal myopathy [11]. This was in contrast with the
FOLFOX regimen, which did not induce any of these effects [11]. These data suggest
that IRI is more impactful on the musculoskeletal system than OXA, and to this effect,
we have recently demonstrated that IRI causes acute cachexia, lean tissue wasting and
skeletal muscle dysfunction [12]. However, whether 5FU also induces cachectic wasting
and skeletal myopathy, independent from the other constituents in the FOLFIRI regimen,
is unclear [13,14]. Such information is of clinical importance so that the risk of cachexia
during administration of FOLFIRI and other 5FU-based regimens can be predicted and
clinically managed.
Chemotherapy-induced skeletal muscle wasting is underlined by compromised pro-
teostasis in favour of protein degradation [6]. It is characterised by a molecular signature
of myopathy involving the activation of the stress-inducible mitogen-activated protein
kinases (MAPK), p38 and ERK1/2 [11], and key transcription factor for inflammatory
genes, nuclear factor-κB (NF-κB) [15]. Since MAPK phosphorylation can interact with
NF-κB phosphorylation during oxidative stress [16], it is suggested that there is a link
between these two target pathways, leading to the induction of a pro-catabolic environ-
ment [17,18]. Specifically, 5FU is a potent activator of p38 MAPK signalling in vitro [19],
and in vivo evidence from the 5FU-based FOLFIRI regimen supports the same—increased
phosphorylation of p38 MAPK associated with enhanced oxidative stress and reduced
mitochondrial quality control signalling [11]. These data are consistent with findings from
our laboratory, where 5FU potentiated mitochondrial superoxide production and reduced
mitochondrial viability in C2C12 skeletal muscle cells [20]. The FOLFIRI regimen also
reduces mitochondrial content, which is associated with abnormalities in muscle morphol-
ogy at the level of the sarcomere [11,21]. This was of interest to our group since we have
recently shown that the chemotherapeutic agent, IRI, compromised cytoskeletal stability
through reducing dystrophin protein expression [12]. While the mechanism underlying
the effect of chemotherapy on skeletal muscle cytoskeletal composition is still undefined, it
may be an event related to chemotherapy-induced NF-κB activation [15], suggesting that
NF-κB activity plays a role in the decay of structural integrity of muscles [22]. Therefore, in
this study, our first aim was to characterise the effect of 5FU treatment on skeletal muscle
mass and function, and to investigate the underlying molecular mechanisms with empha-
sis on the potential connection between p38 MAPK and NF-κB signalling, mitochondrial
dynamics and structural cytoskeletal proteins.
There is estimated to be 3.15 million new CRC cases worldwide in 2040 [1], highlight-
ing the growing burden of cancer and the current need for novel therapeutic strategies to
support current anti-cancer treatments and promote survivability. BGP-15 is a nicotinic
amidoxime derivate and small-molecule therapeutic candidate which acts as a cytoprotec-
tant through the inhibition of poly (ADP) ribose polymerase -1 (PARP-1) and co-induction
of heat shock protein-70 (HSP-70) [23,24]. BGP-15-mediated PARP-1 inhibition and HSP-70
co-induction are associated with improved mitochondrial content, function and oxidative
capacity [25,26]. However, BGP-15 has also been shown to elicit mitoprotection indepen-
dent of these targets, highlighting its pleiotropic efficacy [27]. Consequently, BGP-15 has
promise in the treatment of a range of skeletal myopathies, including diabetes, Duchenne
Muscular Dystrophy and ventilation-induced diaphragm dysfunction (for extensive review
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see [28]). We have evaluated the adjuvant therapeutic potential of BGP-15 to protect against
the induction of skeletal myopathy from chemotherapeutic agents IRI and OXA [12,29],
with mixed efficacy. However, since 5FU is a potent activator of p38 MAPK, and BGP-15
has been shown to inhibit pan-MAPK activity [30], the potential for BGP-15 to be more
efficacious when administered with 5FU is substantial. Thus, our secondary aim was to
evaluate the protective efficacy of BGP-15 adjuvant therapy against 5FU-induced skeletal
myopathy and investigate the underlying mechanisms through which BGP-15 functions as
a p38 MAPK inhibitor in a chemotoxic environment.
2. Results
2.1. Assessment of Body Composition Indices, Skeletal Muscle Mass and Function
To explore the potential contribution of 5FU treatment on the induction of cachexia and
efficacy of 5FU+BGP treatment, we examined a suite of body composition and skeletal muscle
size indices. Interestingly, 5FU did not inhibit growth nor reduce body, lean or fat mass, and
subsequently, 5FU+BGP also did not affect these parameters (Figure 1A–C; Table S1). Consis-
tent with body composition data, raw skeletal muscle mass and skeletal muscle mass to body
mass ratios for EDL, SOL and TA muscles were not significantly different between treatment
groups (Figure 1D), although, 5FU+BGP displayed a trend to increase the TA to body mass
ratio compared to 5FU treatment (p = 0.07, Figure 1D). Organ mass also remained unchanged
between treatment groups (Table S1). We then undertook muscle fibre size analysis in TA
cross-sections, with no significant differences found between treatment groups for the relative
frequency percentage of muscle fibre cross-sectional areas (CSA) (Figure 1E,G) nor the mean
fibre CSA (Figure 1F,G). Next, we assessed the ex vivo contractile function of EDL and SOL
muscles. Neither 5FU, nor 5FU+BGP treatment affected skeletal muscle functional parameters
of EDL or SOL, with no change observed in force–frequency relationships (Figure 2A), force
production characteristics, i.e., Pt, Po, Pt/Po and sPo (Figure 2B).
2.2. Assessment of Cytoskeletal Structural Protein Expression
Previously, we have shown an association between skeletal muscle dysfunction and
reduced expression of proteins associated with the dystrophin-associated protein complex
(DAPC) induced by IRI treatment [12]. Thus, we investigated these parameters in the con-
text of this study. 5FU treatment induced a reduction in the abundance of the cytoskeleton
proteins, desmin and dystrophin (p < 0.05, Figure 3A,B), and 5FU+BGP treatment did not
protect against these changes. There was no impact of 5FU, nor 5FU+BGP, treatment on the
protein expression of additional cytoskeletal structural proteins laminin, β-dystroglycan,
δ-sarcoglycan, dystrobrevin, syntrophin and talin (Figure 3A,B). Next, we explored the
effect of 5FU and 5FU+BGP treatment on AktSer473 phosphorylation, an established target
of Mechanistic Target of Rapamycin Complex 2 (mTORC2) [31]. mTORC2 activity has been
shown to be involved in the regulation of plasma membrane homeostasis and cytoskeletal
organization [32]. Thus, we were interested in mTORC2 activity in the context of the
reduced expression of desmin and dystrophin—the phosphorylation of Akt Ser473 is indica-
tive of mTORC2 activation. We showed that 5FU treatment reduced the phosphorylation
of AktSer473 compared to VEH (p < 0.05, Figure 3C,E), while 5FU+BGP-15 treatment did
not alter the 5FU-induced changes to AktSer473 signalling (Figure 3C).
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Figure 1. The effect of 5-fluorouracil (5FU) and 5FU with BGP-15 (5FU+BGP) treatment on body composition and muscle
size indices. Body composition parameters were measured and presented as pre- and post-treatment data points for (A) body,
(B) lean and (C) fat mass. (D) Hindlimb skeletal muscles extensor digitorum longus (EDL), soleus (SOL), and tibialis
anterior (TA) were weighed post-treatment and data presented as raw mass and muscle to body mass ratios (# p = 0.07;
compared to 5FU). TA cross-sections were H&E-stained and underwent histological fibre size analysis with data presented
as (E) percentage relative frequency distribution of the muscle fibre cross-sectional area (CSA) and (F) mean muscle fibre
CSA. (G) Representative images of H&E-stained TA cross-sections are displayed. Scale bar = 100 µm. n = 7–8 for body
composition indices; n = 4–8 for muscle weights; n = 5–7 for histology. Data are mean ± SEM.
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Figure 2. The effect of 5-fluorouracil (5FU) and 5FU with BGP-15 (5FU+BGP) treatment on skeletal muscle contractile
function. Extensor digitorum longus (EDL) and soleus (SOL) muscles underwent ex vivo assessment of contractile functional
properties, with (A) force–frequency relationships and (B) force production characteristics analyzed, including; Peak twitch
force (Pt), Absolute tetanic force production (Po), twitch to tetanus ratio (Pt/Po), physiological cross-sectional area (pCSA)
and Specific force production (sPo). n = 4–8 for ex vivo contractile function. Data are mean ± SEM.
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Figure 3. The effect of 5-fluorouracil (5FU) and 5FU with BGP-15 (5FU+BGP) treatment on expression of cytoskeletal
structural proteins. Western blotting experiments were undertaken in tibialis anterior (TA) muscle homogenate, with
samples probed for (A,B) cytoskeletal structural proteins including; laminin (LAM), β-dystroglycan (β-DGC), δ-sarcoglycan
(δ-SGC), dystrophin (DYS), dystrobrevin (DBVN), syntrophin (SYTN), desmin (DES) and talin (TAL). (C) Phosphorylated
(Ser473) and total Akt were probed for as an indicator of mammalian target of rapamycin Complex 2 (mTORC2) activity.
(D) Ankrd2 was probed for as a marker of mechano-sensitvit. (E) Representative images for phosphorylated AktSer473,
total Akt and Ankrd2 displayed. Protein expression was normalised to total protein derived from Coomassie Brilliant Blue
(CBB) staining and presented relative to vehicle (VEH) control group. * = p < 0.05; n = 4 for VEH and n = 6–8 for 5FU and
5FU+BGP groups for Western blotting. Data are mean ± SEM.
Given our evidence that 5FU reduced desmin and dystrophin expression and AktSer473
phosphorylation, we investigated potential changes to the mechano-sensitive protein,
ankyrin repeat domain protein 2 (Ankrd2), a member of Muscle Ankyrin Repeat Domain
(MARP) family of titin filament-based stress response proteins [33]. Ankrd2 could be a
target of chemotherapy within skeletal muscle since it is responsive to oxidative stress, a
key mechanism of chemotherapy-induced muscle wasting. We demonstrated that 5FU
treatment did not affect Ankrd2 protein expression (Figure 3D,E). However, 5FU+BGP
treatment increased Ankrd2 expression relative to VEH (p < 0.05, Figure 3D,E). These data
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suggest that BGP-15 may be promoting a futile adaptive stress response that enhances
mechano-sensitivity, despite the perturbed cytoskeletal environment. Full-length blots are
provided in Figure S1 and densitometry summary data are provided in Table S2.
2.3. Assessment of Skeletal Muscle Stress Signalling
Since 5FU has been shown to potently activate p38-MAPK signalling [19], we wanted
to assess the effect of 5FU and 5FU+BGP treatment on p38-MAPK and other molecular
markers of skeletal muscle stress signalling. Consistent with the literature, 5FU treatment
increased the phosphorylation of p38; (p < 0.05, Figure 4A,E). However, the phosphoryla-
tion of other MAPK family members, ERK1/2 or JNK, were not affected (Figure 4B,C,E).
Importantly, 5FU+BGP-15 treatment completely mitigated the 5FU-induced increase in
p38 phosphorylation (p < 0.05, Figure 4A,E). Furthermore, and consistent with BGP-15′s
reported role as a suppressor of MAPK activity [28], 5FU+BGP-15 reduced basal levels of
ERK1/2 and JNK phosphorylation relative to 5FU treatment (p < 0.05, Figure 4B,C,E). 5FU
also increased the phosphorylation of the p65 subunit of NF-κB, a transcriptional media-
tor of pro-inflammatory genes [34], and this was inhibited by co-treatment with BGP+15
(p < 0.05, Figure 4D,E). Full-length blots are provided in Figure S2 and densitometry
summary data are provided in Table S2.
2.4. Assessment of Skeletal Muscle Oxidative Capacity and Mitochondrial Dynamics
Next, we examined skeletal muscle oxidative capacity and markers of mitochondrial
dynamics, as previously we have shown in vitro that 5FU reduces mitochondrial viability
in C2C12 myoblast and myotubes [20]. Further, BGP-15 adjunct therapy alongside the
anti-cancer agent, IRI, increased mitochondrial density and oxidative metabolism [12]. In-
terestingly, skeletal muscle oxidative capacity, as measured histologically via SDH staining,
was not affected by 5FU and 5FU+BGP treatment (Figure 5A–C). 5FU treatment did not
affect mitochondrial content as measured by CS activity (Figure 5D), although 5FU+BGP-15
treatment enhanced CS activity compared to VEH (p < 0.05, Figure 5D). We thought this
may occur through the proposed mechanistic targets of BGP-15, i.e., HSP-70 co-induction
or PARP-1 inhibition [23,24], which augment mitoprotection [25,26]. However, we demon-
strated that there was no change to the protein expression of HSP-70 or PARP-1 from 5FU
or 5FU+BGP treatment (Figure 5E,F,H). Next, we evaluated molecular markers of mitochon-
drial dynamics, including mitochondrial biogenesis, i.e., mitochondrial transcription factor
A (TFAM) and peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1)
isoforms α and β, and mitochondrial fusion, i.e., optic atrophy 1 (OPA1), and fission, i.e.,
dynamin-related protein 1 (DRP1). There were no changes to TFAM, PGC-1α, PGC-1β and
DRP-1 from 5FU or 5FU+BGP treatment (Figure 5G,H), but there was a significant increase
in OPA-1 protein expression from 5FU+BGP treatment compared to VEH, with no change
pertaining to 5FU treatment (Figure 5G,H). This suggests that the increase in mitochon-
drial content with 5FU+BGP may, in part, be a result of enhanced mitochondrial fusion, a
reported pleiotropic effect of BGP-15 [35]. Full-length blots are provided in Figure S2.
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Figure 4. The effect of 5-fluorouracil (5FU) and 5FU with BGP-15 (5FU+BGP) treatment on molecular markers of cellular
stress. Western blotting experiments were undertaken on tibialis anterior muscle homogenate. Samples were probed
for (A) phosphorylated (Thr180/Tyr182) and total p38, (B) phosphorylated (Thr202/Tyr204) and total ERK1/2, (C) phos-
phorylated (Thr183/Tyr185) and total JNK, (D) phosphorylated (Ser536) and total NF-κB subunit protein p65. Data are
presented as phosphorylated to total protein ratios and normalised to total protein derived from Coomassie Brilliant Blue
(CBB) staining and expressed as a relative percentage of the vehicle (VEH) control grou (E) Western blotting and CBB
representative images are displayed. * = p < 0.05; n = 4 for VEH and n = 6–8 for 5FU and 5FU+BGP groups. Data are
mean ± SEM. ** = p < 0.01.
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Figure 5. The effect of 5-fluorouracil (5FU) and 5FU with BGP-15 (5FU+BGP) treatment on skeletal muscle oxidative
capacity and mitochondrial dynamics signalling. Succinate dehydrogenase (SDH) staining was performed on tibialis
anterior (TA) cross-sections. (A) SDH representative images displayed, with data presented as (B) overall SDH intensity and
(C) SDH intensity separated based on oxidative fibre phenotype, i.e., low oxidative, more oxidative and highly oxidative.
TA muscle homogenate was analyzed for (D) citrate synthase (CS) activity, as a marker of mitochondrial density. Further, TA
homogenate was utilized in Western blotting experiments with samples probed for (E) HSP-70, (F) PARP-1 and (G) a suite
of proteins related to mitochondrial dynamics including; TFAM, PGC-1α, PGC-1β, OPA1 and DRP1. Protein expression was
normalised to total protein derived from Coomassie Brilliant Blue (CBB) staining and presented relative to vehicle (VEH)
control group. (H) Western blotting and CBB representative images are displayed. * = p < 0.05; n = 6–8 for SDH histology;
n = 4 for VEH and n = 6–8 for 5FU and 5FU+BGP groups for CS activity and Western blotting. Data are mean ± SEM.
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2.5. Assessment of HSP-70 Expression and Cell Viability in C2C12 Myotubes
Given that we saw no change in HSP-70 protein expression in vivo, we wanted to
understand some of the potential reasons for these data. Thus, we pursued an in vitro
investigation utilising differentiated C2C12 myotubes to delineate the effect of BGP-15
treatment on HSP-70 expression in both a standard and 5FU-induced chemotoxic medium.
Importantly, we demonstrated that BGP-15 increased HSP-70 protein expression compared
to VEH (p < 0.05, Figure 6A). However, in a 5FU-induced chemotoxic medium, the induction
of HSP-70 by BGP-15 was blunted, thus remaining unchanged from VEH (Figure 6A).
Next, we assessed cell viability, through resazurin staining, confirming that 5FU treatment
induced a chemotoxic environment, compared to VEH (p < 0.05, Figure 6B,C). BGP-15
co-treatment displayed a modest improvement in cell viability, compared to 5FU (p < 0.05,
Figure 6B,C). However, it was still significantly reduced compared to both VEH and BGP
control groups (p < 0.05, Figure 6B,C). These data highlight that BGP-15 elicits pleiotropic
cytoprotection, that is in part, independent of HSP-70 induction, which is likely inhibited
when given alongside 5FU. These data support our in vivo data, where there was also no
effect of BGP-15 on HSP-70 expression. Full-length blots are provided in Figure S3.
Figure 6. The effect of BGP-15 (BGP), 5-fluorouracil (5FU) and 5FU with BGP (5FU+BGP) treatment
on HSP-70 expression and cell viabilityC2C12 myotubes were treated with BGP, 5FU and 5FU
with BGP before being prepared as lysates for Western blotting experiments. (A) C2C12 lysates
were then probed for HSP-70, with protein expression normalised to total protein derived from
Coomassie Brilliant Blue (CBB) staining data and data presented as a percentage of the vehicle
control group (VEH). (B) Cell viability was analyzed via the resazurin cell viability assay, with data
presented as a percentage of VEH. (C) Representative images for the cell viability assay are displayed.
Scale bar = 100 µm. * = p < 0.05; n = 3–4 for all C2C12 experiments. Data are mean ± SEM.
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3. Discussion
The major finding of this study is that metronomic delivery of 5FU reduced the
expression of key cytoskeletal proteins, desmin and dystrophin and increased the phos-
phorylation of p38 MAPK and NF-κB, events that are evident in other models of muscle
wasting. Despite this, 5FU did not impact body composition indices or alter whole muscle
mass or muscle fibre size. While our data suggest that these 5FU-mediated events are not
sufficient to elicit a myopathic phenotype, they may, prime the muscle to be more suscepti-
ble to adverse effects of other constituents of multi-agent regimens, such as LV and IRI for
FOLFIRI or LV and OXA for FOLFOX. Furthermore, this study found that, while BGP-15
co-therapy did not alter the 5FU-induced decrease in cytoskeletal protein abundance, it
mitigated the increase in p38 MAPK and NF-κB phosphorylation, which was associated
with improved mitochondrial content and fusion dynamics. Together these data suggest
that while 5FU primes the muscle for myopathy, BGP-15 has pleiotropic cytoprotectant
functions that protect against the activation of this molecular stress signature.
5FU treatment reduced the expression of key cytoskeletal proteins, desmin, an inter-
mediate filament that provides stability to sarcomeres, and dystrophin, a large protein that
connects the actin cytoskeleton to the sarcolemma, with the potential to compromise the
structural organization of skeletal muscle and alter intracellular signalling. Previously, we
have demonstrated that chemotherapeutic agent, IRI, also reduces dystrophin expression,
which was associated with reduced AktSer473 phosphorylation, a direct substrate of kinase
mTORC2 [12,31]. Phosphorylation of AktSer473 is a putative indicator of plasma membrane
homeostasis and cytoskeletal organization [32]. As such, our finding of reduced AktSer473
phosphorylation concomitant with a reduced desmin and dystrophin protein expression,
suggests that 5FU may have disrupted sarcolemmal homeostasis, cytoskeletal organiza-
tion and intracellular signalling. Consistent with our previous findings, BGP-15 adjuvant
therapy was not protective against the chemotherapy-induced reduction in the expression
of cytoskeletal proteins [12]. Desmin and dystrophin-related myopathies are often associ-
ated with debilitating dysfunction [36,37] and myopathy is compounded in desmin and
dystrophin double-knockout mice, which manifest a remarkable dystrophic phenotype
with profound deterioration of sarcomere organisation and Z-line alignment [38]. Our
data suggest that a critical level of desmin and dystrophin loss must occur before there
is evidence of functional and structural alterations. Indeed, Baretto et al. showed that
when administered over a longer duration (twice a week for 5 consecutive weeks), the
5FU-based FOLFIRI regimen reduced skeletal muscle function concurrent with aberrant
skeletal muscle morphology [11], highlighting a temporal component to observing loss of
function from metronomic delivery of chemotherapeutic agents. It would be of interest
in future studies to evaluate the expression of key cytoskeletal proteins and sarcomere
morphology in response to 5FU treatment longitudinally, to determine whether the muscles
can recover or whether they retain a propensity for myopathy, which may be exacerbated,
for example, by mechanical stressors such as exercise. Interestingly, we demonstrated novel
evidence that BGP-15 adjuvant therapy promotes the expression of mechano-sensitive
MARP family member, Ankrd2 [39]. We hypothesize that BGP-15 is escalating an adaptive
stress response targeting tension dynamics by enhancing mechano-sensitivity within the re-
duced desmin and dystrophin environment. Since Ankrd2 is localized to titin filaments and
Ankrd2 abundance is similarly increased in a conditional titin knockout mouse model [40],
it is possible that increased mechano-sensitivity and remodelling of titin dynamics are
an additional pleiotropic effect of BGP-15, which, although not warranted in this study
because 5-FU did not impact contractile function, contributes to its protective effect against
loss of muscle function with other chemotherapeutic agents [12].
Chemotherapeutic agents, irrespective of class, induce the activation of p38 MAPK
signalling as a function of their cytotoxic nature [41]. We demonstrated that 5FU treatment
increased the phosphorylation of p38 MAPK in skeletal muscle, which was consistent
with findings from Barreto et al. where 5FU, administered as a constituent of the FOLFIRI
chemotherapy regimen, led to enhanced p38 MAPK activity [11]. Contrary to the FOLFIRI
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regimen, neither ERK1/2 nor JNK phosphorylation were increased by 5FU treatment [11].
MAPKs have been shown to exhibit specific time- and dose-dependent profiles during
oxidative stress in C2C12 myoblasts [16]. Thus, we cannot rule out that ERK1/2 and
JNK could have been activated at an earlier timepoint. Additionally, it is well acknowl-
edged that p38 MAPK is positively associated with the NF-κB complex, with both targets
activated in response to oxidative stress [16] and mediators of inflammatory cytokine
production [19,42], although NF-κB signalling is purported to have a greater role in skeletal
muscle wasting conditions (for extensive review [34]). Indeed, we showed that 5FU-
induced p38 MAPK activation was associated with an increase in the phosphorylation of
NF-κB subunit protein, p65, an event depicting transactivation of NF-κB, which is essential
for enhancing its transcriptional activity [43]. Damrauer et al. similarly demonstrated
that anti-cancer agent, cisplatin, enhances NF-κB transcriptional activity through stim-
ulating the DNA-heterodimerization of subunits p50 and p65 in C2C12 myotubes [15].
However, chemotherapy-induced NF-κB activity in vitro reduced myotube diameter [15],
while in the current study, we saw no evidence of skeletal muscle atrophy. This suggests
the magnitude and persistency of NF-κB activity is important for atrophy induction, as the
metronomic regimen used in our study was protective of skeletal muscle mass. Interest-
ingly, BGP-15 mitigated the 5FU-induced increase in the phosphorylation of p38 MAPK
and NF-κB subunit protein p65 in our study. Further, BGP-15 reduced the phosphorylation
of MAPKs ERK 1/2 and JNK relative to 5FU. This is consistent with findings from Sarszegi
et al., where BGP-15 suppressed MAPK phosphorylation, which was enhanced during
imatinib (tyrosine kinase inhibitor)-induced cardiotoxicity [30]. While it is unsurprising
that BGP-15 acted as a repressor of MAPK activity, it is novel that BGP-15 also inhibited
the 5FU-induced activation of NF-κB. These data could suggest a negative feedback mech-
anism, since 5FU-induced p38 MAPK phosphorylation in vitro has previously been shown
to enhance the production of inflammatory cytokines, IL-6, TNF-α and IL-1β [19], which
are known stimulants of NF-κB activity [42]. Future studies are required to confirm that
5FU-induced phosphorylation of p38 MAPK and NF-κB subunit protein, p65, enhances
inflammatory cytokine production and that BGP-15 has an anti-inflammatory effect in
this context.
In this study, we observed no evidence of 5FU-induced alterations to oxidative capac-
ity, mitochondrial content or mitochondrial dynamics signalling, suggesting that 5FU may
require other cytotoxic-agents (e.g., the FOLFIRI regimen [11]) to perturb mitochondrial ac-
tivity in vivo. This is in contrast to in vitro models where we have shown that 5FU induces
mitochondrial stress in cultured C2C12 myoblasts and myotubes [20], where direct and
persistent interaction between 5FU and muscle cells appears more impactful. Consistent
with previous findings, we demonstrated that BGP-15 increases mitochondrial density
when administered alongside chemotherapy [12]. However, in contrast, we did not observe
a BGP-15-induced inhibition of PARP-1 expression in this study. Further, we did not detect
a change in HSP-70 expression in vivo at the time of tissue collection, although, we did find
that the addition of BGP-15 to 5FU-treated C2C12 myotubes blunted the induction of HSP-
70. We hypothesize that 5FU enhances the production of pro-inflammatory cytokines [19],
which have been shown to act as repressors to heat shock factor-1 transcription, inhibiting
the HSP-70 adaptive stress response [44,45]. This has led our laboratory, and others, to
postulate that BGP-15 acts as a cytoprotectant in response to chemical or disease-induced
stress, with the underlying protective mechanisms inconsistent and largely dependent
on the challenge elicited by a given stressor [27,46]. It is considered that BGP-15 may
elicit cytoprotection through pleiotropic mechanisms that regulate mitochondrial quality
control [47]. Indeed, we showed that BGP-15 adjuvant therapy did not affect mitochon-
drial biogenesis or fission signalling but did consistently promote mitochondrial fusion
signalling through increased OPA1 expression (compared to VEH), which was associated
with enhanced mitochondrial density.
An important, yet paradoxical, finding of this study was that 5FU treatment did not
elicit any consequences on body composition indices, skeletal muscle mass or function,
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despite the alterations to skeletal muscle stress signalling (i.e., p38 and NF-κB phosphory-
lation) that are usually associated with the induction of chemotherapy-induced cachexia
and skeletal myopathy [11,15]. The lack of change to these physiological parameters from
5FU treatment may be due to the metronomic delivery of chemotherapy, which typically
elicits less systemic toxicity than administration of single maximum tolerable dose (MTD)
bolus or sequential daily treatments [48,49]. Metronomic delivery could activate an adap-
tive hormetic response which prevents the induction of skeletal myopathy in the face of
low-grade stress signalling. Interestingly, when comparing to models that deliver 5FU
sequentially in a shorter and more intense regimen, such as the one used in VanderVeen
et al., i.e., 35 mg/kg once daily for 5 days (175 mg/kg cumulative), body mass was reduced,
but there was no impact on skeletal muscle mass [13]. Further, Chen et al. utilised a similar
regimen, i.e., 40 mg/kg once daily for 4 days (160 mg/kg cumulative), where there was
evidence of a latent loss of body and skeletal muscle mass when harvested 4 days post
final 5FU injection [14]. This highlights that 5FU-induced changes to muscle mass are
dependent on the intensity of regimen and require a certain temporal component before
they are physiologically exhibited. This concept is mirrored by functional studies, in which
metronomic delivery of 5FU did not affect whole body grip strength but did when deliv-
ered in a short and intense regimen [50]. Given these data, we believe that metronomic 5FU
may prime skeletal muscle with the molecular signature for myopathy without exerting a
great enough challenge to result in physiological consequences.
There were some limitations to the study presented. Here, we utilised 6-week-old
mice and treated them over 2 weeks, up to 8 weeks of age. Mice are generally considered
to approach a plateau of their growth phase at 8 weeks of age, thus we treated them
during this development period before measuring the impact of our interventions at sexual
maturity. This might contribute to the outcome of the data, compared to conducting these
interventions on sexually mature mice. However, both paediatric and adult cancer patients
receive chemotherapy, and can each be impacted by cachexia. Further investigation is
warranted in this model, with particular emphasis on a time-course study, involving both
short-term and long-term experimental endpoints to investigate the temporal nature of the
suite of proteins measured alongside the physiological parameters.
4. Materials and Methods
4.1. Animals
4.1.1. Ethical Approval
All experimental procedures were approved by the Victoria University Animal Ethics
Committee (AEETH15/006) and conformed to the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes.
4.1.2. Experimental Design and Treatments
Six week old male Balb/c mice were acquired from the Animal Resource Centre
(ARC, Murdoch, WA, Australia) and randomly allocated to treatment groups (n = 8) upon
arrival. Mice were housed on a 12 h light/dark cycle with ad libitum access to food
(AIN-93G, Speciality Feeds, Glen Forrest, WA, Australia) and water supply throughout the
experiments. Mice were administered either vehicle (VEH; 10% dimethyl sulfoxide (DMSO)
in sterile water), 5-fluorouracil (5FU; 23 mg/kg (Sigma Aldrich, North Ryde, Australia)
dissolved in 10% DMSO) or BGP-15 adjuvant therapy with 5FU (5FU+BGP; 15 mg/kg
(BGP-15 donated by N-gene R&D, Australia) dissolved in 10% DMSO). The 5FU dose and
regimen were used by us previously [51,52] and were effective at offsetting chemotoxicity
symptoms associated with irinotecan treatment in skeletal muscle [12]. Treatments were
administered via intraperitoneal injection 6 times over a 15 day period (i.e., on day 1, 3
5, 8, 10 and 12), resulting in a cumulative dose of 138 mg/kg and 90 mg/kg, of 5FU and
BGP-15, respectively. The dosage and frequency of 5FU administration, with and without
BGP-15, was based on previous published studies by us and our collaborators [12,51].
Repetitive chemotherapy dosing at set intervals (i.e., metronomic delivery) is compatible
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with the clinical treatment of cancer in contrast to the administration of a single bolus
maximum tolerated dose that is often investigated in basic science: we have discussed this
approach extensively before [48]. The selected dose is equivalent to the standard human
dose per body surface area [53], and has proven efficacy in mouse models of cancer [54]
and elicits toxicity in other physiological systems [51,52]. The BGP-15 dose was shown to
elicit skeletal muscle protection against chemotoxicity by us previously [12,29].Animals
were weighed prior to the commencement of treatment (pre), on each day of treatment and
at the experimental endpoint (post).
4.2. Body Composition
Echo Magnetic Resonance Imaging (echoMRI) was utilized to assess the effect of 5FU
treatment and BGP-15 co-therapy on body composition indices of lean and fat mass. Live
mice were placed into an echoMRI body composition analyzer (EMR-150, Echo Medical
Systems, Houston, TX, USA) on day 1 (pre) and day 15 (post) of the treatment protocol, as
previously described [48]. Lean and fat mass was quantified via triplicate scans spaced 30 s
apart and reported as the mean of these triplicate scans.
4.3. Surgery
At the conclusion of the treatment regimen and following the final echoMRI scan,
mice were deeply anaesthetised via isoflurane inhalation, before non-recovery surgery
commenced. Muscles of interest were surgically excised for ex vivo analysis in the fol-
lowing order: (1) right extensor digitorum longus (EDL) and soleus (SOL) muscles for the
assessment of contractile properties; (2) right tibialis anterior (TA) muscles were harvested
and immediately snap-frozen for Western blotting experiments; (3) left TA muscles were
weighed and prepared for histological assessment prior to snap-freezing. The remaining
tissues were then harvested (i.e., the left EDL and SOL), weighed and snap-frozen.
4.4. Ex Vivo Skeletal Muscle Contractile Function
Ex vivo evaluation of skeletal muscle contractile properties were performed as previ-
ously described by us [12,55], using the predominantly fast-twitch muscle, EDL and the
predominantly slow-twitch muscle, SOL. Briefly, muscles were tied with 4.0 surgical silk
thread, dissected from the hindlimb and attached to a transducer in individual organ baths
of a Myodynamics Muscle Strip Myograph System (DMT, Aarhus, Denmark). Each organ
bath was filled with Krebs solution (118 mM NaCl, 1 mM MgSO4.7H2O, 4.75 mM KCl, 1
mM Na2HPO, 2.5 mM CaCl2, 24 mM NaHCO3 and 11 mM glucose; pH 7.4) bubbled with
carbogen (5% CO2 in O2) and maintained at a temperature of 30 ◦C. Data were collected
and analyzed using LabChart Pro version 8.0 software (ADInstruments, Dunedin, New
Zealand). Supramaximal stimulations were delivered by flanking electrodes. Optimal
length (Lo) was established through sequential twitch contractions with incremental stretch,
with peak twitch force (Pt) derived at Lo. Peak tetanic force (Po) was obtained by delivering
pulse trains at 350msec and 500msec for the EDL and SOL, respectively at increasing fre-
quencies. Twitch to tetanus ratio (Pt/Po) was assessed as an indicator of elasticity/stiffness.
Specific force (sPo) was obtained by normalising force to the physiological cross-sectional
area (pCSA) as previously described [56].
4.5. Skeletal Muscle Histology
All histological experiments were completed as previously described [12,29]. To
determine whether 5FU had atrophic effects on skeletal muscle and, subsequently, whether
BGP-15 co-therapy could rescue any atrophy, we histologically assessed TA muscles which
were cryopreserved in optimal cutting temperature compound (Sakura Finetek, Torrance,
CA, USA). TA’s were sectioned (10 µm, −20 ◦C, Leica CM1950) and mounted onto glass
slides, then stained with haematoxylin and eosin (H&E), for muscle fibre size analysis,
and succinate dehydrogenase (SDH), as an indicator of oxidative capacity. H&E-stained
slides were processed on a Zeiss Axio Imager Z2 microscope (Carl Zeiss MicroImaging
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GmbH, Göttingen, Germany), and imaged at 50x magnification, with analysis conducted
as described previously [57]. SDH slides were processed the same way and imaged at 20x
magnification. SDH images were analyzed in two ways: first, the whole cross-section of
the TA was circled and the intensity density of the SDH stain was assessed using ImageJ;
and second, the staining intensity of 600 individual fibres was measured using ImageJ
with the maximum intensity density identified and used to determine a bottom, middle
and top third. The percentage of fibres that fell into each third was determined and the
data displayed as less oxidative (bottom third), more oxidative (middle third) and highly
oxidative (top third).
4.6. Western Blotting Analyses
Western blotting was utilised to explore the effect of 5FU treatment and BGP-15
co-therapy on molecular signalling pathways surrounding cell stress, mitochondrial bio-
genesis and cytoskeletal structural proteins. All Western blotting protocols were completed
as previously described [12]. Frozen TA muscles were homogenized using an Omni Tis-
sue Homogenizer (TH220, Omni International, Kennesaw, GA, USA) for 20 s in ice-cold
Western Immunoprecipitation Kinase (WIK) buffer (40 mM Tris, pH 7.5; 1 mM EDTA;
5 mM EGTA; 0.5% TritonX-100; 25 mM β-glycerophosphate; 25 mM NaF; 1 mM Na3VO4;
10 g/ml leupeptin; and 1 mM PMSF). Muscle homogenate was centrifuged at 3500 rpm
for 5 minutes at 4 ◦C, before the pellet was resuspended and the muscle homogenate was
frozen for future analysis. Protein concentrations were determined using a DC assay kit
(Bio-Rad Laboratories, Hercules, CA, USA), to ensure equal loading on the gels. Sam-
ples were prepared with equivalent amounts of protein in either 2X SDS sample buffer
(20% (v/v) glycerol; 100 mM Tris-Base, pH 6.8; 4% (w/v) SDS; 0.017% (w/v) bromophe-
nol blue; 0.25 M dithiothreitol (DTT)), heated for 5 minutes at 95 ◦C, and subjected to
electrophoretic separation on 7.5–12% SDS-acrylamide gels. Following electrophoretic
separation, proteins were transferred to PVDF membrane, blocked with 5% not-fat milk
powder in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 hour followed by
an overnight incubation at 4 ◦C with primary antibody dissolved in TBST containing
either 1% BSA or 3% non-fat milk powder. The following primary antibodies were used:
anti-phospho AktSer473 (1:3000; #4060; Cell Signalling Technology (CST)), anti-Akt (1:2000;
#4691; CST), anti-Ankrd2 (1:1000; #11821-1-AP; Proteintech), anti-β-Dystroglycan (1:1000;
MANDAG2 (7 D11); DSHB), anti-δ-Sarcoglycan (1:1000; ab137101; Abcam), anti-Desmin
(1:1000; #5332; CST), anti-Dystrobrevin (1:500; #610766; BD Biosciences), anti-Dystrophin
(1:500; ab15277; Abcam), anti-phospho ERK1/2 (1:750; #9101; CST), anti-ERK1/2 (1:1000;
#9102; CST), anti-DRP1 (1:1000; #8570; CST), anti-HSP-70 (1:1000; ADI-SPA-812; Enzo
Life Sciences), anti-phospho JNK (1:750; #4668; CST), anti-JNK (1:1000; #9252; CST), anti-
Laminin (1:2000; L9393; Sigma-Aldrich), anti-OPA1 (1:1000; #80471; CST), anti-phospho
p38 (1:750; #4511; CST), anti-p38 (1:1000; #9212; CST), anti-phospho p65 (1:750; #3033;
CST), anti-p65 (1:1000; #8242; CST), anti-PARP-1 (1:1000; #9542, CST), anti-PGC-1α (1:1000;
AB3242; Sigma-Aldrich), anti-PGC-1β (1:1000; ab176328; Abcam), anti-syntrophin (1:750;
MA1-745; Invitrogen), anti-talin (1:200; T3287; Merck-Millipore) and anti-TFAM (1:3000;
ab131607; Abcam). After overnight incubation, membranes were washed 3 separate times
for 10 minutes each in TBST and then probed with a horseradish peroxidase-conjugated
secondary antibody (1:5000; anti-rabbit IgG or 1:20,000; anti-mouse IgG, Vector Laborato-
ries) in 5% not-fat milk powder in TBST for 1 hour at room temperature. Following another
set of 3 separate 10-minute washes in TBST, the blots were developed with a DARQ CCD
camera mounted to a Fusion FX imaging system (Vilber Lourmat, Eberhardzell, Germany)
using ECL Clarity reagent (Biorad, Hercules, CA, USA). Once images were captured, the
membranes were stained with Coomassie Blue and then normalised to total protein. Den-
sitometric measurements were carried out using FusionCAPTAdvance software (Vilber
Lourmat, Eberhardzell, Germany).
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4.7. Citrate Synthase Activity
Citrate Synthase (CS) activity was measured as a marker of mitochondrial density [58].
Homogenized TA muscles in WIK buffer (as described above) were added to the reagent
cocktail (100 mM Tris Buffer, 1 mM DTNB, 3 mM Acetyl CoA) and to initiate the reaction,
oxaloacetate (10 mM) was added just prior to measuring CS activity spectrophotometrically
(412 nm, 25 ◦C, 5 min). CS activity was calculated using the extinction coefficient of 13.6 [59]
and expressed relative to muscle wet weight.
4.8. Cell Culture Experiments
4.8.1. C2C12 Cell Culture
C2C12 myoblasts (ATCC) were cultured and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 1% antibi-
otic/antimycotic, 1% Glutamax, and 1 mM sodium pyruvate (all cell culture reagents were
purchased from Gibco Invitrogen, Carlsbad, CA, USA). Cells were incubated at 37 ◦C
with 5% CO2. To induce differentiation, cells were plated at high confluence (~90%) and
changed to differentiation medium (supplemented DMEM containing 2% horse serum).
Cells were maintained in differentiation medium for 4–5 days to form myotubes before
commencing drug treatments. Differentiated myotubes were treated with vehicle control
(VEH; DMSO), BGP-15 control (BGP; 100 mM), 5FU (1 mM) and the 5FU+BGP combination
for 24 h prior to assays and protein collection.
4.8.2. Protein Collection
Cells were lysed and collected for Western blotting in radio immunoprecipitation
buffer (RIPA; 1 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCl, 140 mM sodium chloride, 10%
sodium deoxycholate, and 1% triton-X 100) containing protease and phosphatase inhibitors
(Sigma Aldrich, St. Louis, MO, USA). The lysates were centrifuged at 13,000 rpm at 4 ◦C
for 30 minutes. The supernatants were collected and stored at −80 ◦C and the pellets
discarded. Western blotting was performed as described above.
4.8.3. Resazurin Cell Viability Assay
Confluent myotubes were treated with drugs of interest for up to 24 h in differen-
tiation medium prior to resazurin viability assay (Sigma Aldrich, St. Louis, MO, USA)
measurements. The resazurin assay solution was prepared at a 1:10 dilution of resazurin in
DMEM differentiation medium. Once the dye was added the plates were shielded from
light and stored at 37 ◦C with 5% CO2 for two hours. Following the incubation period,
the supernatant was transferred to an opaque 96 well plate for fluorometric reading (at
560 nm; Varioskan Flash plate reader) using SkanIt RE software (Thermo Fisher, Waltham,
MA, USA). Plates containing myotubes were rinsed with ice cold PBS and fixed with 100%
methanol, followed by Diff-Quick staining (Histolabs, Kew East, Australia). Plates were
left to dry overnight prior to imaging with an Olympus IX81 microscope (Olympus, Tokyo,
Japan) to observe morphological changes.
4.9. Statistics
Data are presented as the mean ± standard error of the mean (SEM). Data were
analyzed using Graphpad prism v9 (GraphPad Software, San Diego, CA, USA). A one-way
ANOVA was utilised to detect treatment differences for parametric data, while a two-
way repeated measures ANOVA was used to detect differences between treatment and
stimulation frequency/time for force–frequency relationships. Tukey’s post hoc test was
utilised for multiple comparisons testing, with an α-value of 0.05 considered significant.
5. Conclusions
This is the first study to demonstrate that metronomic delivery of 5FU reduces the
expression of desmin and dystrophin, which is not affected by BGP-15. However, BGP-15
mitigated the 5FU-induced increase in p38 and NF-κB phosphorylation, which was associ-
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ated with BGP-15 increasing mitochondrial density and fusion dynamics. Paradoxically,
metronomic delivery of 5FU did not impact body composition indices, nor skeletal muscle
mass and function. These findings suggest that the metronomic delivery of 5FU may prime
skeletal muscle with a molecular signature for myopathy but does not exert a great enough
challenge to result in physiological consequences within the treatment duration employed
in this study. Overall, these data highlight novel mechanisms surrounding the impact of
5FU treatment and BGP-15 adjuvant therapy on skeletal muscle, supporting the need for
further investigation, particularly in cancer-burdened mice to enhance the translational
potential of the dataset.
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10.3390/ph14050478/s1, Table S1: Organ to body mass ratios, Figure S1: Full-length Western blot
images relating to the skeletal muscle homogenate data presented in Figure 3, Figure S2: Densitometry
summary data from representative Western blot images, Table S2 Densitometry summary data from
representative Western blot images, Figure S3: Full-length Western blot images relating to the C2C12
myotube cell lysate data presented in Figure 6.
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